| Overview |
| bs-10059r-rbitc-100ul |
| Cullin 5 Polyclonal Antibody, RBITC Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Horse, Rabbit |
| Specifications |
| RBITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Cullin 5 |
| 701-780/780 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 1729 |
| Cytoplasm |
| CUL 5; CUL-5; CUL5; CUL5_HUMAN; Cullin-5; Cullin5; VACM 1; VACM-1; VACM1; Vasopressin activated calcium mobilizing receptor 1; Vasopressin activated calcium mobilizing receptor; Vasopressin-activated calcium-mobilizing receptor 1. |
| Core component of multiple SCF-like ECS (Elongin-Cullin 2/5-SOCS-box protein) E3 ubiquitin-protein ligase complexes, which mediate the ubiquitination and subsequent proteasomal degradation of target proteins. As a scaffold protein may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme. The functional specificity of the E3 ubiquitin-protein ligase complex depends on the variable substrate recognition component. ECS(SOCS1) seems to direct ubiquitination of JAk2. Seems to be involved poteosomal degradation of p53/TP53 stimulated by adenovirus E1B-55 kDa protein. May form a cell surface vasopressin receptor. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz